Supplementary Data from K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)
Abstract
Supplementary Data from K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib MesylateKeywords
This publication has 0 references indexed in Scilit: